New Drug Candidate that Reprograms the Immune System Shows Promise as a Brain Cancer Treatment

Why It Matters

Glioblastoma’s median survival under 15 months underscores an urgent need for novel therapies, and a CAR‑T that dismantles both tumor cells and their niche could dramatically extend patient outcomes. Successful translation would also validate uPAR as a pan‑cancer immunotherapy target, opening new commercial avenues.

Key Takeaways

• uPAR CAR‑T eliminates glioblastoma tumors in mouse models.
• Targets uPAR on cancer cells and supportive stromal niche.
• Preclinical data suggest potential first‑in‑human trial within two years.
• uPAR also being explored as target in lung and pancreatic cancers.

Pulse Analysis

Glioblastoma remains the deadliest primary brain tumor, with median survival under 15 months despite surgery, radiation and temozolomide chemotherapy. The disease’s infiltrative nature and blood‑brain barrier have limited the impact of conventional drugs, prompting a surge in immunotherapy research. Recent advances in chimeric antigen receptor (CAR) T‑cell platforms have shown activity against hematologic malignancies, yet solid‑tumor applications lag behind. Against this backdrop, McMaster University’s preclinical study offers a rare glimpse of a potentially transformative approach.

The therapy, dubbed uPAR CAR‑T, engineers patient‑derived T cells to express a receptor that binds the urokinase‑type plasminogen activator receptor (uPAR), a protein overexpressed on glioblastoma cells and their supportive stromal niche. In mouse models, a single infusion of 1 × 10⁶ uPAR‑CAR T cells eradicated established tumors and prevented recurrence, outperforming unmodified T cells. Targeting uPAR also disrupts the tumor‑microenvironment, cutting off signals that promote angiogenesis and invasion. Parallel programs at Memorial Sloan Kettering and Columbia have identified uPAR as a viable target in lung and pancreatic cancers, hinting at cross‑tumor applicability.

With preclinical efficacy established, Singh’s team is already negotiating IND‑enabling studies and exploring partnerships for manufacturing the autologous cell product. A first‑in‑human trial could begin within two years, offering patients access to a therapy that attacks both cancer cells and their supportive matrix. Commercially, a successful uPAR CAR‑T could command premium pricing similar to existing CAR‑T approvals, while also opening a pipeline for other uPAR‑driven malignancies. The breakthrough underscores a broader shift toward precision immunotherapies that remodel the tumor ecosystem rather than merely killing cells.